See more : Ito En, Ltd. (ITONF) Income Statement Analysis – Financial Results
Complete financial analysis of Japan Lifeline Co., Ltd. (7575.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Japan Lifeline Co., Ltd., a leading company in the Medical – Devices industry within the Healthcare sector.
- Altshuler Shaham Finance Ltd (ALTF.TA) Income Statement Analysis – Financial Results
- Dragon Mountain Gold Limited (DMG.AX) Income Statement Analysis – Financial Results
- Vicon Holdings Limited (3878.HK) Income Statement Analysis – Financial Results
- Public Joint Stock Company “Ashinskiy metallurgical works” (AMEZ.ME) Income Statement Analysis – Financial Results
- Camurus AB (publ) (0RD1.L) Income Statement Analysis – Financial Results
Japan Lifeline Co., Ltd. (7575.T)
About Japan Lifeline Co., Ltd.
Japan Lifeline Co., Ltd., a medical device company, develops, produces, imports, distributes, and trades in cardiovascular related medical devices in Japan. The company's cardiac rhythm management products include cardiac pacemakers, implantable cardioverter defibrillators, subcutaneous implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators and pacemakers, automated external defibrillators, and cardiopulmonary resuscitation support devices; and electrophysiology/ablation products comprise electrophysiological and ablation catheters, irrigated tip ablation catheters, endoscopic balloon ablation systems, esophageal temperature monitoring systems, internal atrial cardioversion systems, and radio-frequency transseptal needles. Its cardiovascular and endografting products consist of vascular and open stent grafts, and abdominal stent-grafts; and transvascular intervention products include PTCA and PTA guide wires, PTCA balloon catheters, radiofrequency wires, and atrial septal defect closure devices. The company offers gastrointestinal intervention products that consist of radiofrequency ablation systems, self-expandable colonic stents, and endoscopic guidewires. Japan Lifeline Co., Ltd. was incorporated in 1981 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.38B | 51.75B | 51.47B | 51.29B | 51.76B | 45.53B | 42.30B | 37.18B | 30.54B | 25.70B | 24.37B | 21.94B | 23.14B | 22.36B | 22.09B | 19.84B | 19.84B | 18.15B | 19.19B | 18.03B |
| Cost of Revenue | 20.40B | 21.86B | 22.63B | 22.62B | 22.57B | 17.70B | 15.72B | 15.18B | 13.29B | 11.74B | 11.63B | 10.68B | 11.20B | 11.36B | 11.02B | 10.63B | 10.63B | 9.58B | 9.93B | 9.56B |
| Gross Profit | 30.99B | 29.90B | 28.84B | 28.66B | 29.19B | 27.82B | 26.58B | 22.00B | 17.25B | 13.96B | 12.74B | 11.26B | 11.94B | 11.01B | 11.07B | 9.21B | 9.21B | 8.57B | 9.27B | 8.47B |
| Gross Profit Ratio | 60.30% | 57.77% | 56.02% | 55.89% | 56.40% | 61.11% | 62.83% | 59.17% | 56.49% | 54.32% | 52.26% | 51.32% | 51.61% | 49.22% | 50.09% | 46.44% | 46.44% | 47.23% | 48.28% | 46.99% |
| Research & Development | 2.37B | 2.32B | 2.16B | 1.67B | 1.74B | 1.43B | 1.12B | 1.05B | 933.00M | 794.00M | 636.00M | 554.60M | 515.72M | 371.89M | 381.03M | 225.03M | 225.03M | 202.89M | 257.51M | 151.10M |
| General & Administrative | 1.13B | 905.00M | 737.00M | 625.00M | 1.43B | 1.50B | 1.52B | 1.37B | 1.27B | 1.14B | 1.12B | 991.49M | 1.41B | 1.33B | 1.40B | 2.84B | 1.39B | 871.33M | 880.01M | 805.14M |
| Selling & Marketing | 674.00M | 495.00M | 355.00M | 279.00M | 753.00M | 833.00M | 650.00M | 552.00M | 517.00M | 414.00M | 408.00M | 371.21M | 424.88M | 441.23M | 400.31M | 439.49M | 439.49M | 411.31M | 480.90M | 467.00M |
| SG&A | 1.80B | 1.40B | 1.09B | 904.00M | 2.18B | 2.33B | 2.17B | 1.92B | 1.79B | 1.56B | 1.53B | 1.36B | 1.83B | 1.77B | 1.80B | 3.28B | 1.83B | 1.28B | 1.36B | 1.27B |
| Other Expenses | 15.93B | -47.00M | -10.00M | -19.00M | 199.00M | -27.00M | 57.00M | 206.00M | -94.00M | 131.00M | 21.00M | 99.86M | 62.73M | 105.53M | 90.68M | 329.82M | 329.82M | 381.14M | 225.92M | 173.30M |
| Operating Expenses | 20.10B | 19.05B | 18.85B | 18.29B | 18.75B | 17.29B | 15.90B | 14.31B | 13.55B | 12.11B | 11.51B | 10.49B | 8.41B | 7.88B | 7.69B | 8.91B | 7.01B | 6.45B | 8.20B | 7.62B |
| Cost & Expenses | 40.49B | 40.91B | 41.49B | 40.91B | 41.32B | 34.99B | 31.62B | 29.49B | 26.83B | 23.85B | 23.15B | 21.17B | 19.61B | 19.24B | 18.71B | 19.54B | 17.64B | 16.03B | 18.12B | 17.18B |
| Interest Income | 156.00M | 105.00M | 63.00M | 325.00M | 540.00M | 407.00M | 159.00M | 94.00M | 78.00M | 31.00M | 14.00M | 10.13M | 7.70M | 2.58M | 5.08M | 5.92M | 5.92M | 6.26M | 4.75M | 3.38M |
| Interest Expense | 26.00M | 34.00M | 76.00M | 183.00M | 141.00M | 49.00M | 55.00M | 49.00M | 52.00M | 39.00M | 34.00M | 30.59M | 23.24M | 19.17M | 16.23M | 31.53M | 31.53M | 15.59M | 20.05M | 8.82M |
| Depreciation & Amortization | 1.79B | 1.88B | 1.93B | 1.84B | 1.46B | 1.26B | 1.10B | 960.00M | 795.00M | 770.00M | 640.00M | 565.70M | 461.36M | 298.68M | 276.44M | 206.54M | 206.54M | 264.53M | 324.68M | 376.09M |
| EBITDA | 12.39B | 11.71B | 12.05B | 6.57B | 11.90B | 12.18B | 11.77B | 8.97B | 4.41B | 2.96B | 1.58B | 1.55B | 2.23B | 2.09B | 1.65B | 766.50M | 2.75B | 1.36B | 1.93B | 1.44B |
| EBITDA Ratio | 24.11% | 24.26% | 22.67% | 23.97% | 24.17% | 26.79% | 27.75% | 23.70% | 14.45% | 10.99% | 8.17% | 7.05% | 17.57% | 15.89% | 17.11% | 4.31% | 13.88% | 15.70% | 9.51% | 7.97% |
| Operating Income | 10.89B | 10.84B | 9.97B | 10.37B | 10.43B | 10.53B | 10.67B | 7.69B | 3.70B | 1.85B | 1.22B | 774.93M | 3.53B | 3.13B | 3.38B | 305.61M | 2.20B | 2.12B | 1.07B | 850.67M |
| Operating Income Ratio | 21.20% | 20.94% | 19.38% | 20.21% | 20.16% | 23.12% | 25.23% | 20.67% | 12.12% | 7.18% | 5.00% | 3.53% | 15.25% | 13.98% | 15.30% | 1.54% | 11.11% | 11.68% | 5.58% | 4.72% |
| Total Other Income/Expenses | -317.00M | -1.05B | 68.00M | -5.83B | -9.00M | 275.00M | -56.00M | 272.00M | 814.00M | 113.00M | -524.00M | 317.56M | -1.94B | -1.50B | -2.17B | 222.82M | -1.68B | -927.12M | 518.12M | 201.96M |
| Income Before Tax | 10.58B | 9.79B | 10.04B | 4.54B | 10.43B | 10.80B | 10.62B | 7.96B | 4.51B | 1.96B | 695.00M | 1.09B | 1.59B | 1.62B | 1.21B | 528.44M | 528.44M | 1.19B | 1.59B | 1.05B |
| Income Before Tax Ratio | 20.58% | 18.92% | 19.51% | 8.85% | 20.14% | 23.73% | 25.10% | 21.40% | 14.78% | 7.62% | 2.85% | 4.97% | 6.88% | 7.26% | 5.49% | 2.66% | 2.66% | 6.57% | 8.28% | 5.84% |
| Income Tax Expense | 3.06B | 2.90B | 2.56B | 2.54B | 2.68B | 3.08B | 3.14B | 2.61B | 1.71B | 833.00M | 898.00M | 571.84M | 872.06M | 850.67M | 650.57M | 292.21M | 292.21M | 684.37M | 810.73M | 595.18M |
| Net Income | 7.52B | 6.89B | 7.48B | 2.00B | 7.75B | 7.72B | 7.48B | 5.35B | 2.80B | 1.12B | -202.00M | 519.73M | 720.52M | 772.99M | 562.80M | 236.23M | 236.23M | 508.45M | 777.46M | 457.45M |
| Net Income Ratio | 14.63% | 13.32% | 14.54% | 3.90% | 14.97% | 16.96% | 17.68% | 14.39% | 9.18% | 4.37% | -0.83% | 2.37% | 3.11% | 3.46% | 2.55% | 1.19% | 1.19% | 2.80% | 4.05% | 2.54% |
| EPS | 98.72 | 88.22 | 93.12 | 24.90 | 96.55 | 96.04 | 98.51 | 71.91 | 36.71 | 13.02 | -2.34 | 6.01 | 8.34 | 8.95 | 6.51 | 2.15 | 2.72 | 5.93 | 8.79 | 5.03 |
| EPS Diluted | 98.72 | 88.22 | 93.12 | 24.90 | 96.55 | 95.86 | 98.44 | 71.91 | 36.71 | 13.02 | -2.34 | 6.01 | 8.34 | 8.95 | 6.51 | 2.15 | 2.72 | 5.93 | 8.67 | 5.03 |
| Weighted Avg Shares Out | 76.12M | 78.12M | 80.37M | 80.32M | 80.25M | 80.41M | 75.91M | 74.41M | 76.41M | 86.41M | 86.41M | 86.41M | 86.42M | 86.42M | 86.42M | 86.42M | 86.90M | 85.78M | 82.06M | 83.94M |
| Weighted Avg Shares Out (Dil) | 76.12M | 78.12M | 80.37M | 80.32M | 80.25M | 80.57M | 75.97M | 74.41M | 76.41M | 86.41M | 86.41M | 86.41M | 86.42M | 86.42M | 86.42M | 86.42M | 86.90M | 85.78M | 89.63M | 83.94M |
Source: https://incomestatements.info
Category: Stock Reports